DR.WU Skincare Co., Ltd. (6523) AI Stock Analysis

DR.WU Skincare Co., Ltd.

(TPEx:6523)

Select Model

Rating:71Outperform

Price Target:TWD 87.00▲(7.01% Upside)

Action:initiatedcoverage

Date:11/09/26

The score is anchored by DR.WU's strong financial profile: an essentially debt-free balance sheet, ~26% return on equity, premium ~69% gross margins and near-full conversion of profit into free cash flow. This is tempered by a clear earnings downcycle, with revenue down ~5.5%, net income down ~26% and margins compressing. Valuation support is strong, with a P/E of ~11.9 and a very high dividend yield backed by cash flow, but the technical picture is the main drag: the stock trades well below all key moving averages with negative MACD, and while RSI and Stochastic readings are deeply oversold, the prevailing trend remains downward. Low beta (0.19) suggests limited market-driven volatility. No earnings call or corporate event data was available, so those factors were excluded.

Positive Factors

Conservative Balance SheetMinimal leverage gives DR.WU substantial financial flexibility and resilience through changing demand conditions. Strong returns on equity also indicate efficient use of capital, supporting continued operations and investment without the funding pressure associated with a heavily indebted balance sheet.

Negative Factors

Revenue and Earnings ContractionRecent contraction in sales and net income signals weakening demand momentum and reduces near-term operating leverage. If the slowdown persists, it could constrain reinvestment, dilute the benefits of the company's strong margins, and make future earnings growth more dependent on renewed consumer demand.

DR.WU Skincare Co., Ltd. (6523) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 3.63B
Dividend Yield: 12.30%
Average Volume (3M): 27.05K
Price to Earnings (P/E): 12.6
Beta (1Y): 0.16
Revenue Growth: -11.85%
EPS Growth: -23.46%
Country: TW
Employees: 150
Sector: General
Sector Strength: 55
Industry: Household & Personal Products

DR.WU Skincare Co., Ltd. Business Overview & Revenue Model

Company Description

Dr. Wu Skincare Co., Ltd. is a company that develops and distributes a broad spectrum of skincare and cosmetic products, serving both the Taiwanese domestic market and an international clientele. Their comprehensive product range includes facial clea...

DR.WU Skincare Co., Ltd. Financial Statement Overview

Summary

DR.WU combines premium profitability with a fortress balance sheet, but growth has clearly stalled. Revenue fell about 5.5% to NT$1.17 billion and net income dropped roughly 26% to NT$350 million, with operating margin compressing from ~48% to ~38%. Offsetting this, gross margin remains elevated near 69%, debt-to-equity is just 0.03 (effectively debt-free), equity funds ~85% of assets, and return on equity is healthy at ~26%. Cash generation is a standout: operating cash flow of ~NT$341 million converted into ~NT$335 million of free cash flow, covering ~98% of net income under a capital-light model, though free cash flow also declined from NT$434 million a year earlier. A high-quality but decelerating business with a shrinking asset base.

Income Statement

68Positive

Balance Sheet

86Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.07B	1.17B	1.24B	1.14B	926.79M	1.11B
Gross Profit	717.19M	805.59M	878.08M	814.02M	658.01M	694.36M
EBITDA	362.22M	452.53M	604.58M	535.46M	434.30M	385.02M
Net Income	297.83M	350.27M	476.25M	424.73M	339.98M	296.24M
Balance Sheet
Total Assets	1.64B	1.59B	1.75B	1.77B	1.78B	1.83B
Cash, Cash Equivalents and Short-Term Investments	1.00B	836.02M	908.72M	1.28B	1.37B	1.41B
Total Debt	35.55M	40.98M	46.77M	5.05M	15.68M	25.50M
Total Liabilities	370.50M	235.86M	294.71M	291.12M	254.22M	296.10M
Stockholders Equity	1.27B	1.35B	1.46B	1.47B	1.53B	1.53B
Cash Flow
Free Cash Flow	369.44M	335.01M	434.43M	389.16M	324.24M	286.23M
Operating Cash Flow	375.22M	340.92M	437.18M	392.44M	325.83M	289.60M
Investing Cash Flow	103.39M	128.40M	-89.21M	-108.64M	-332.73M	812.05M
Financing Cash Flow	-461.05M	-460.49M	-505.36M	-460.47M	-370.21M	-785.36M

DR.WU Skincare Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6523 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6703	77Outperform	TWD 3.44B	8.36	―	7.77%	5.97%	37.00%
TW:1730	71Outperform	TWD 3.19B	10.48	―	5.95%	1.66%	8.74%
TW:6523	71Outperform	TWD 3.63B	12.63	―	12.30%	-11.85%	-23.46%
TW:4439	59Neutral	TWD 3.72B	10.54	―	4.14%	19.84%	223.34%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:5321	42Neutral	TWD 3.36B	-17.46	―	―	-21.62%	-494.73%
TW:4120	40Underperform	TWD 3.85B	-6.75	―	8.91%	3.77%	-78.32%

* General Sector Average

Performance Comparison

TW:6523 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6523	DR.WU Skincare Co., Ltd.	81.30	-25.40	-23.81%
TW:1730	Farcent Enterprise Co., Ltd.	50.40	0.29	0.58%
TW:4120	Orient Europharma Co., Ltd.	44.90	2.73	6.48%
TW:4439	TST Group Holding Ltd.	98.00	10.91	12.53%
TW:5321	United Recommend International Co., Ltd.	57.20	18.50	47.80%
TW:6703	Shiny Brands Group Co., Ltd.	94.50	-1.08	-1.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

DR.WU Skincare Co., Ltd. AI Stock Analysis